MYP_096147
Risankizumab
Anticancer
Immunology
▸
Immune modulation
▸
Immunomodulatory activity
Standard
449 amino acids
C2200H3398N580O677S16
Standard
QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDQTIHWMRQAPGQGLEWIGYIYPRDDSPKYNENFKGKVTITADKSTSTAYMELSSLRSEDTAVYYCAIPDRSGYAWFIYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
49317.03 Da
8.34
4.55
3.55
0.0101
-0.44
0.48
0.01
44.84
67.42
0.0958
80790.00
81415.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Amino Acid Composition
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
RECORD: Rec_0396352
VERIFIED: NO
Provenance & Taxonomy
Homo sapiens [Animal]
Monoclonal antibody
9606
Structure & Mods
linear peptide/protein therapeutic [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Immunomodulatory
The half-life of risankizumab is about 28 days in patients with plaque psoriasis.[FDA label]
RECORD: Rec_0414276
VERIFIED: NO
Provenance & Taxonomy
Homo sapiens [Animal]
Monoclonal antibody
9606
Structure & Mods
linear peptide/protein therapeutic [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Anticancer
Immunomodulatory
The half-life of risankizumab is about 28 days in patients with plaque psoriasis.[FDA label]